Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ENOB HV 21

X
Drug Profile

ENOB HV 21

Alternative Names: Adaptive allogenic cell therapy - Renovaro Biosciences; Allogenic natural killer and gamma delta T-cell therapy; Allogenic NK and GD-T Cell therapy; ENOB-HV-21; KIR/HLA mismatched allogenic NK and gamma-delta T cell therapy; NK-GDT therapy; RENB-HV-21

Latest Information Update: 21 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enochian BioSciences
  • Developer Renovaro Biosciences; Seraph Research Institute
  • Class NKT cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended HIV infections

Most Recent Events

  • 09 Aug 2023 Enochian BioSciences is now called Renovaro Biosciences
  • 31 Dec 2022 Suspended - Preclinical for HIV infections in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top